Project Grant F32CA294616
Award Date 12/25/25
Completion Date 7/31/28
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $219,491 to the Mayo Clinic Jacksonville to conduct research on the epigenetic regulation of T cell metabolism and immune functions by the SIRT6 protein. The research aims to understand how SIRT6 impacts the metabolic activity and effector functions of tumor-reactive T cells, with the goal of identifying ways to boost T cell metabolism and enhance cancer immunotherapies. The study will...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,291,419.00 to Mayo Clinic Arizona to conduct a Phase 1 clinical trial using autologous, MUC1-activated T cells expanded from peripheral blood in patients with relapsed and resistant ovarian cancer. The award period runs from September 1, 2024 to August 31, 2028. This research aims to advance innovative cellular immunotherapy approaches to transform...
- This $549,460 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida to study the role of the BCL11B transcription factor in regulating CD8+ T cell response and memory in tumor microenvironments. The award aims to establish the transcriptional programs and epigenomic landscape controlled by BCL11B in mouse T cells, with the goal of understanding...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $639,004 to Mayo Clinic from January 1, 2025 to December 31, 2029 to conduct research on using a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key products and services to be delivered under this award include: Collecting and processing pre- and post-treatment tumor tissue and peripheral blood samples...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Mayo Clinic Jacksonville (a nonprofit corporation registered as Scott Lynch MD) to develop a first-in-class non-muscle myosin II (NMII) inhibitor, MT-125, for the treatment of glioblastoma. The $607,634 award, effective January 1, 2025 through December 31, 2029, supports research to uncover the mechanisms behind the synergistic effects of MT-125 when combined with...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,000.00 to Mayo Clinic to conduct research aimed at enhancing the effectiveness of immune checkpoint blockade (ICB) immunotherapy for renal cell carcinoma (RCC). The project seeks to demonstrate that disrupting the ubiquitination or phosphorylation of the RIPK1 protein in RCC tumor cells can increase their susceptibility to killing by T cells in a TNF-dependent manner, thereby...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....
- This Cooperative Agreement award, valued at $704,622.00, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Mayo Clinic Arizona, a child entity of Mayo Collaborative Services, Inc. The award supports preclinical studies on the immunoprevention of multiple myeloma, a type of blood cancer. The research aims to develop faithful, immunocompetent mouse models that can recapitulate the progression from smoldering multiple myeloma to symptomatic multiple...
- The National Cancer Institute (NCI) awarded a $112,234 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Van Andel Research Institute (VAI) in Michigan. The grant runs from August 1, 2025 to July 31, 2027 and aims to investigate the role of the PTGIR-prostacyclin signaling pathway in driving T cell exhaustion and suppressing anti-tumor immunity. The project will use mouse models to test whether pharmacologically inhibiting PTGIR can reinvigorate tumor-infiltrating...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...